Tag Archives: Regenerative Medicine

Hot Investor Mandate 4: Venture Arm of Global Medical Device Company Looking to Invest In or Partner with Early-Stage Companies Developing Platforms for Regenerative Medicine

26 Apr

A venture arm of a global medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools, is focused on developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient. The firm is focused on early-stage technologies and is flexible in terms of deal structures and partnerships with startup companies, including seed stage equity investments, strategic partnerships, and joint ventures/collaborations. The firm looks to be a dedicated partner working closely with startups to advance technologies and build companies. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s core focus is on tools and bioprocessing platforms for regenerative medicine including, but not limited to, cell and gene therapies. Interests also include therapies that rely on immature or insufficient manufacturing tools and processes. Some examples of the firm’s products include a platelet lysate culture media to expand cell lines, automated fill/finish and thawing devices, a cryogenic vial to protect samples throughout lab processes, a blood filtration system for autologous cell therapy preparation and more.

The firm has no strict requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Life Science Investor Mandate 2: Foundation Allocates to Companies Working to Cure Retinal Diseases

20 Nov

A foundation based in the Eastern US typically makes allocations to companies in the range of $1-$8 million, and is capable of providing $10-$15 million over the investments lifetime. The firm primarily funds companies located in the United States but will consider opportunities located globally as well. The firm provides equity capital, and does look for a return, though percentages taken are generally less than more financially-motivated investors, and all profits are reinvested back into the fund. Ideally, the firm would like to allocate to 3-4 companies over the next 6-9 months.

The foundation’s mission is to fund research that will provide preventions, treatments and cures for the entire spectrum of retinal degenerative diseases. Currently, they are looking to fund companies in the therapeutics sector, and will consider companies working in areas of Small Molecules, Biologics, Gene Therapy, and Regenerative Medicine that target those indications. The firm primarily funds companies that are just preparing to enter the IND enabling stage, but they will consider companies in all stages of clinical trials.

The foundation often invests into companies that do not have complete management teams, and looks to utilize the foundations expertise and network in the retinal disease space to help companies grow. The foundation has many experts in the field that will help aid companies as well as a registry of potential patients for clinical trials.

%d bloggers like this: